CoChat

Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling

Open access
Aiysha Thompson, Kanamarlapudi · 2013 · Clinical & Experimental Pharmacology
Cited by 33

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form.Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and kidney failure.Glucagon like Peptide-1 (GLP-1) is an effective insulinotropic agent and therefore its effects on insulin secretion have been greatly examined for more than two decades.It is a polypeptide hormone secreted by the intestinal L-cells into the blood in response to food uptake.GLP-1 has a very short half-life in vivo due to the rapid proteolytic degradation by Dipeptidyl Peptidase IV (DPP-IV).Therefore DPP-IV resistant GLP-1 analogues, Exenatide and Liraglutide, have been developed and are currently being used in the treatment of type 2 diabetes.GLP-1 agonist functions by binding to its receptor, GLP1R, on the cell surface.The GLP-1R belongs to the class B peptide receptor family based on its structure and function.The binding of GLP-1 to its receptor results in activation of Gαs coupled adenylyl cyclase and the production of cyclic Adenosine Monophosphate (cAMP), which enhances glucose-induced insulin secretion.Continuous GLP-1R activation also causes insulin secretion and pancreatic islet β-cell proliferation and neogenesis.The GLP-1R is internalised following its activation, which regulates the biological responsiveness of the receptor.Structurally the GLP-1R contains a large N-terminal extracellular domain (TM1-TM7) joined by three intracellular loops (ICL1, ICL2, ICL3) and three extracellular loops (ECL1, ECL2, ECL3), and an intracellular C-terminal domain.These domains play critical roles in GLP-1R trafficking to the cell surface, and also in agonist dependent activation and internalisation of the receptor.This review is focused on type 2 diabetes, its treatment with GLP-1, GLP-1R structure and function, and the physiological affects resulting from GLP-1R activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4172/2161-1459.1000138

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 33

Metadata

Authors
Aiysha Thompson, K.
Venue
Clinical & Experimental Pharmacology
Published
2013
Volume
03
Issue
04
ISSN
2161-1459 (ISSN-L)
OpenAlex
W2168620887
Cited by
33
References
47
FWCI
1.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. https://app.cochat.ai/papers/10.4172/2161-1459.1000138
The paper
Aiysha Thompson, K. (2013). Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clinical & Experimental Pharmacology. https://doi.org/10.4172/2161-1459.1000138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.